DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Asfotase alfa

Asfotase alfa

  • European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa As a Treatment for Patients with Hypophosphatasia

    European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa As a Treatment for Patients with Hypophosphatasia

  • Asfotase Alfa for Infants and Young Children with Hypophosphatasia: 7 Year Outcomes of a Single-Arm, Open-Label, Phase 2 Extension Trial

    Asfotase Alfa for Infants and Young Children with Hypophosphatasia: 7 Year Outcomes of a Single-Arm, Open-Label, Phase 2 Extension Trial

  • Asfotase Alfa (Strensiq) for Treatment of Hypophosphatasia in Infants and Children

    Asfotase Alfa (Strensiq) for Treatment of Hypophosphatasia in Infants and Children

  • Transaction Drug 1St (DIN) 2Nd (PIN) 3Rd (PIN) 4Th (PIN) 5Th (PIN) 6Th

    Transaction Drug 1St (DIN) 2Nd (PIN) 3Rd (PIN) 4Th (PIN) 5Th (PIN) 6Th

  • CHMP Agenda of the 10-13 October 2016 Meeting

    CHMP Agenda of the 10-13 October 2016 Meeting

  • New Drug Approvals and Extended Indications for Infants, Children, and Adolescents Marcia L

    New Drug Approvals and Extended Indications for Infants, Children, and Adolescents Marcia L

  • ENTRY WATCH 2016 Published by the Patented Medicine Prices Review Board June 2018 Meds Entry Watch, 2016 Is Available in Electronic Format on the PMPRB Website

    ENTRY WATCH 2016 Published by the Patented Medicine Prices Review Board June 2018 Meds Entry Watch, 2016 Is Available in Electronic Format on the PMPRB Website

  • Strensiq, INN-Asfotase Alfa

    Strensiq, INN-Asfotase Alfa

  • Asfotase Alfa (Strensiq) Reference Number: CP.PHAR.328 Effective Date: 03/17 Coding Implications Last Review Date: 03/17 Revision Log

    Asfotase Alfa (Strensiq) Reference Number: CP.PHAR.328 Effective Date: 03/17 Coding Implications Last Review Date: 03/17 Revision Log

  • Inventory of Community and National Incentive Measures to Aid The

    Inventory of Community and National Incentive Measures to Aid The

  • Lists of Medicinal Products for Rare Diseases in Europe*

    Lists of Medicinal Products for Rare Diseases in Europe*

  • Strensiq, INN-Asfotase Alfa

    Strensiq, INN-Asfotase Alfa

  • Odontoblastic Differentiation of Dpscs

    Odontoblastic Differentiation of Dpscs

  • Pharmacy Medical Necessity Guidelines: Strensiq™ (Asfotase Alfa)

    Pharmacy Medical Necessity Guidelines: Strensiq™ (Asfotase Alfa)

  • Lysosomal Storage Disorders

    Lysosomal Storage Disorders

  • WO 2017/031114 Al 23 February 2017 (23.02.2017) P O P C T

    WO 2017/031114 Al 23 February 2017 (23.02.2017) P O P C T

  • Specialty Drug List

    Specialty Drug List

  • Colorado Medicaid Program

    Colorado Medicaid Program

Top View
  • Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
  • Self-Administered Specialty Drug List
  • Alphabetical Listing by Therapeutic Category Dod UNIFORM
  • Aralast NP™, Glassia™, Prolastin®-C
  • Specialty Formulary
  • Specialty Pharmacy Program Drug List
  • Asfotase Alfa (Strensiq™) EOCCO POLICY
  • 57 Orphan Drugs Approved by the EC Between 2012 and 2016 Were Found, of Which 40 (70.2%) Had Been Authorised in Spain
  • Premium Value
  • STRENSIQ Safely and Effectively
  • Procedures, Programs and Drugs You Must Precertify
  • State and Specialty Pharmacy Drug Reimbursement Rates
  • Partnerre Trigger Pharmaceuticals (At 2.6.20)
  • Health Plan Insights
  • Reimbursement Criteria for Frequently Requested Drugs
  • State and Specialty Pharmacy Drug Reimbursement Rates
  • ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
  • Enzyme Related Therapies


© 2024 Docslib.org    Feedback